Published in Eur J Pharmacol on May 22, 2015
Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes. J Neuroinflammation (2016) 0.76
The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro. Front Pharmacol (2016) 0.75
Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation. J Neuroinflammation (2016) 0.75
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol (2005) 5.95
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 5.67
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med (1993) 4.94
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem (1995) 3.78
Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther (2003) 3.29
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol (2009) 2.74
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics (2010) 2.52
Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 2.14
IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia (2005) 1.56
Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol (1999) 1.53
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol (2011) 1.36
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther (1982) 1.35
Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol (2010) 1.33
Regulation of NF-κB signaling by the A20 deubiquitinase. Cell Mol Immunol (2012) 1.33
Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol (2003) 1.31
CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci (2006) 1.31
SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol (1998) 1.29
The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci (2007) 1.27
Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol (2000) 1.27
Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem (1996) 1.20
The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat (2005) 1.15
Presence of the acute phase protein, bikunin, in the endometrium of gilts during estrous cycle and early pregnancy. Biol Reprod (2001) 1.13
Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia (2009) 1.08
Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. Neurobiol Dis (2010) 1.08
Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther (2002) 1.07
Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res (2007) 1.07
MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation (2008) 1.07
The cytokine IL-1beta activates IFN response factor 3 in human fetal astrocytes in culture. J Immunol (2005) 1.05
Ethanol-induced modulation of inducible nitric-oxide synthase activity in human A172 astrocytoma cells. Alcohol Clin Exp Res (2002) 1.01
Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol (2013) 0.99
Low-grade endotoxemia in patients with severe autism. Neurosci Lett (2010) 0.99
beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther (1988) 0.94
Ethanol increases nuclear factor-kappa B activity in human astroglial cells. Neurosci Lett (2004) 0.93
Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci (2011) 0.92
The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol (2007) 0.91
Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J Neuroimmunol (2010) 0.91
In vivo expression of proinflammatory cytokines in HIV encephalitis: an analysis of 11 autopsy cases. Neuropathology (2009) 0.90
Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology (2013) 0.89
In situ detection of intracerebral cytokine expression after human brain contusion. Neurosci Lett (2004) 0.87
Inflammation in neurological and psychiatric diseases. Inflammopharmacology (2012) 0.87
Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J Neurochem (2005) 0.86
Role of disorder in IκB-NFκB interaction. IUBMB Life (2012) 0.86
Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol (2008) 0.84
A systems biology approach to suppress TNF-induced proinflammatory gene expressions. Cell Commun Signal (2013) 0.82
Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells. Biochim Biophys Acta (2013) 0.82
Possible antinociceptive mechanisms of opioid receptor antagonists in the mouse formalin test. Pharmacol Biochem Behav (2003) 0.81
Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor. Mol Pharmacol (1990) 0.81
Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation. J Neuroinflammation (2012) 0.80
Morphine withdrawal stress modulates lipopolysaccharide-induced interleukin 12 p40 (IL-12p40) expression by activating extracellular signal-regulated kinase 1/2, which is further potentiated by glucocorticoids. J Biol Chem (2011) 0.80
Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats. Psychopharmacology (Berl) (2011) 0.80
Evaluation of receptor mechanism mediating fentanyl analgesia and toxicity. Eur J Pharmacol (1991) 0.79
Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice. J Pharmacol Exp Ther (2001) 0.79
Neuromelanin inhibits CXCL10 expression in human astroglial cells. Neurosci Lett (2010) 0.78
Chronic inorganic mercury exposure induces sex-specific changes in central TNFα expression: importance in autism? Neurosci Lett (2011) 0.78
The μ opioid receptor is not involved in ethanol-stimulated dopamine release in the ventral striatum of C57BL/6J mice. Alcohol Clin Exp Res (2011) 0.77
Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes. Neurochem Int (2013) 0.76
K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA). Eur J Pharmacol (2014) 0.76